我們已在上線！進一步了解

Ovid Therapeutics

OVID

市值 US$4.2億

2.15 USD

-0.11

4.87%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

2.15

0.00

0%

1天

-4.87%

5天

-12.24%

1個月

-19.78%

3個月

-12.24%

6個月

-23.21%

今年迄今

22.16%

1年

36.94%

5年

-39.44%

10年

-82.45%

關於： Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.

員工： 23

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 16.7%

中性 66.7%

負面 16.7%

Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer

NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced the appointment of Matt David, M.D., as Chief Financial Officer.

Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer

Ovid Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company's management will participate in two upcoming investor conferences: Cantor Global Healthcare Conference – Wednesday, September 9 at 2:10 pm ET H.C.

Ovid Therapeutics to Participate in Upcoming Investor Conferences

Zacks Investment Research

What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?

Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now?

Zacks Investment Research

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

Ovid Therapeutics (OVID) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.06 per share a year ago.

Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates

Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including financial results for the second quarter ended June 30, 2026.

Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results

Zacks Investment Research

Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline

Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline

Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development

NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced several strategic appointments strengthening its executive leadership team to support the Company's next phase of development.

Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development

Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally

Ovid Therapeutics is rated a Buy, driven by risk-adjusted undervaluation and a $193 million cash runway through 2029. OVID's lead asset, OV329, targets drug-resistant epilepsies with a differentiated safety profile; Phase 2 trials begin Q2 2026. Secondary asset OV4071, now in Phase 1, pivots toward the lucrative schizophrenia/psychosis market, offering pipeline diversification.

Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally

Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329 And TSC/IS Expansions

Ovid Therapeutics is upgraded from 'Hold' to 'Buy' as OV329 advances past safety hurdles at higher doses. The company's OV329 demonstrates best-in-class potential, with a superior safety and pharmacologic profile versus first-generation Sabril, targeting rare epilepsies. Phase 2 expansion includes POC studies in photosensitive seizures, treatment-resistant FOS, TSC-associated seizures, and infantile spasms, with key catalysts in 2026-2027.

Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329 And TSC/IS Expansions

Ovid Therapeutics to Participate in Upcoming Investor Conferences

NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today announced that the Company's management will participate in two upcoming investor conferences:

Ovid Therapeutics to Participate in Upcoming Investor Conferences

查看新聞排名

價格圖表採用Lightweight Charts™實作